prospidium has been researched along with Esophageal Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Filippenko, VI; Kusherbaev, SK; Turganbaeva, DA; Urbisinov, ZhK | 1 |
| Asanov, AA; Azhigaliev, NA; Fel'dman, SZ; Kusherbaev, SK; Sadykov, SS | 1 |
| Akhmetov, MM; Akimova, AIa; Chissov, VI; Il'ina, AI; Mamontov, AS; Rusakov, IG; Shchitkov, KG; Volokhov, AB | 1 |
| Azhigaliev, NA; Kusherbaev, SK; Sadykov, SS | 1 |
1 trial(s) available for prospidium and Esophageal Neoplasms
| Article | Year |
|---|---|
[Prospidin in combination with gamma teletherapy in treating esophageal cancer].
Topics: Adult; Aged; Clinical Trials as Topic; Drug Evaluation; Esophageal Neoplasms; Evaluation Studies as Topic; Female; Gamma Rays; Humans; Male; Middle Aged; Piperazines; Prospidium; Radioisotope Teletherapy; Radiotherapy Dosage | 1979 |
3 other study(ies) available for prospidium and Esophageal Neoplasms
| Article | Year |
|---|---|
[Results of radiation and chemoradiation therapy in esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Esophageal Neoplasms; Gamma Rays; Humans; Methotrexate; Metronidazole; Prospidium; Radiotherapy Dosage; Remission Induction; Time Factors | 1990 |
[Immediate results of the use of prospidin in a cyanoacrylate glue compound in cancer of the esophagus].
Topics: Animals; Carcinoma, Adenoid Cystic; Carcinoma, Squamous Cell; Carcinosarcoma; Cyanoacrylates; Drug Evaluation; Esophageal Neoplasms; Female; Humans; Macromolecular Substances; Male; Middle Aged; Palliative Care; Piperazines; Postoperative Complications; Prospidium; Rats; Rats, Inbred Strains; Sarcoma, Experimental; Tissue Adhesives | 1989 |
[Efficacy of the conservative treatment of patients with inoperable esophageal cancer].
Topics: Antineoplastic Agents; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Male; Methotrexate; Prognosis; Prospidium | 1988 |